FDA hits ALX On­col­o­gy with par­tial clin­i­cal hold, cap­ping PhII stud­ies at 50 pa­tients while safe­ty check en­sues

ALX On­col­o­gy $ALXO has been hit with a par­tial clin­i­cal hold.

The Burlingame, CA-based biotech an­nounced the news Mon­day morn­ing say­ing their Phase II stud­ies in ad­vanced head and neck squa­mous cell car­ci­no­ma can be­gin, but en­roll­ment must be capped at 50 pa­tients across both tri­als. ALX can in­crease en­roll­ment past that lev­el once a non-clin­i­cal safe­ty study has been com­plet­ed, which the com­pa­ny says is cur­rent­ly un­der­way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.